Influence of the use of Renewable Compatibility Agent Wood Plastic Composite (WPC)

The growing interest in using recycled and natural materials in the application of new composites in recent years implies ecological, economic and versatility benefits. Wood plastic composite (WPC) are considered very attractive materials, as they allow the use of polymers of recycled or virgin origin, associated with forestry by-products. The present work aims to investigate the influence on the mechanical, thermal and morphological resistance of WPC, using oleic acid and glycerol as renewable coupling agents. Composites were also prepared with a commercial compatibility agent in its formulation - maleic anhydride grafted polypropylene (MAPP) - under the same conditions. The composites were prepared in a single-screw extruder, with fixed contents of 5% sawdust with 95% virgin polymer, of this total, 2% were coupling agents: MAPP, oleic acid or glycerol, according to the desired composition. To be evaluated as changes in mechanical properties, tensile and impact strength tests were performed on specimens obtained through the injection molding process. The fracture surfaces of specimens tested in tensile tests were examined using images generated by scanning electron microscopy. The thermal stability of the composites was also investigated by thermogravimetric analysis. The use of glycerol and oleic acid improved the mechanical properties of the composite. An increase in tensile strength is observed when glycerol is added in composite. As for impact strength, the addition of glycerol or oleic acid was around 58% higher in impact strength when compared to without coupling agent. Glycerol and oleic acid are renewable, low-cost alternative to be a potential substitute for the commercial coupling agent MAPP, especially when the main requirement is to obtain better impact resistance properties

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival